Literature DB >> 22699819

Apelin, plasmatic osmolality and hypotension in dialyzed patients.

Valeria Cernaro1, Antonio Lacquaniti, Giuseppina Lorenzano, Saverio Loddo, Adolfo Romeo, Valentina Donato, Rosaria Lupica, Antoine Buemi, Michele Buemi.   

Abstract

BACKGROUND/AIMS: To evaluate the balance between arginine-vasopressin (AVP) and apelin during hemodialysis and its role in hypotension onset and in the inflammation status.
METHODS: We enrolled 50 patients chronically treated with hemodialysis. We assessed plasmatic osmolality, AVP, apelin, mean blood pressure (BP), high-sensitivity C-reactive protein (hsCRP) and β(2)-microglobulin.
RESULTS: Apelin rises during dialytic treatment (from 0.68 ± 0.34 to 1.89 ± 0.56 pg/ml, p < 0.0001), while plasmatic osmolality (from 325 ± 4.54 to 311 ± 1.20 mosm/kg H(2)O, p < 0.0001), AVP (from 4.28 ± 1.12 to 2.48 ± 0.50 pg/ml, p < 0.0001) and mean BP (from 124 ± 6 to 110 ± 7 mm Hg, p < 0.0001) decrease. At multivariate regression with respect to apelin, only mean BP remains (r = -0.95, p < 0.0001). We also correlated the AVP/apelin ratio with BP. Moreover, apelin is inversely related to hsCRP (r = -0.79, p < 0.0001).
CONCLUSIONS: The AVP/apelin balance changes with plasmatic osmolality variations induced by hemodialytic sessions and could represent a physiopathological marker of arterial hypo- and hypertension. Finally, apelin appears inversely related to inflammation markers.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699819     DOI: 10.1159/000337104

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Sodium removal and plasma tonicity balance are not different in hemodialysis and hemodiafiltration using high-flux membranes.

Authors:  Vincenzo La Milia; Chiara Ravasi; Fabio Carfagna; Elena Alberghini; Ivano Baragetti; Laura Buzzi; Francesca Ferrario; Silvia Furiani; Gaia Santagostino Barbone; Giuseppe Pontoriero
Journal:  J Nephrol       Date:  2019-01-10       Impact factor: 3.902

2.  Association of Predialysis Calculated Plasma Osmolarity With Intradialytic Blood Pressure Decline.

Authors:  Finnian R Mc Causland; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2015-05-12       Impact factor: 8.860

Review 3.  Osmolality and blood pressure stability during hemodialysis.

Authors:  Anika T Singh; Finnian R Mc Causland
Journal:  Semin Dial       Date:  2017-07-09       Impact factor: 3.455

4.  Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial.

Authors:  Finnian R Mc Causland; Brian Claggett; Venkata S Sabbisetti; Petr Jarolim; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2019-04-27       Impact factor: 8.860

5.  Changes in Plasma Copeptin Levels during Hemodialysis: Are the Physiological Stimuli Active in Hemodialysis Patients?

Authors:  Esmée M Ettema; Johanna Kuipers; Solmaz Assa; Stephan J L Bakker; Henk Groen; Ralf Westerhuis; Carlo A J M Gaillard; Ron T Gansevoort; Casper F M Franssen
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 6.  Mechanisms for hemodynamic instability related to renal replacement therapy: a narrative review.

Authors:  Adrianna Douvris; Khalid Zeid; Swapnil Hiremath; Sean M Bagshaw; Ron Wald; William Beaubien-Souligny; Jennifer Kong; Claudio Ronco; Edward G Clark
Journal:  Intensive Care Med       Date:  2019-08-12       Impact factor: 17.440

Review 7.  The Elabela-APJ axis: a promising therapeutic target for heart failure.

Authors:  Zheng Ma; Juan-Juan Song; Sara Martin; Xin-Chun Yang; Jiu-Chang Zhong
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

8.  Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.

Authors:  Nicola E Owen; Duuamene Nyimanu; Rhoda E Kuc; Paul D Upton; Nicholas W Morrell; Graeme J Alexander; Janet J Maguire; Anthony P Davenport
Journal:  Peptides       Date:  2020-11-07       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.